Laboratory Testing Guidelines

Introduction to Laboratory Testing

• Baseline urine drug testing (UDT) should be performed before initiating therapy to establish a patient's substance use profile, as recommended by the CDC, with a high strength of evidence supporting this recommendation 1, 2
• Clinicians should use opioid-specific immunoassays when monitoring for specific drugs like oxycodone, and consider lower thresholds when adherence monitoring is the primary goal, as suggested by the American Society of Addiction Medicine and the Clinical Infectious Diseases guidelines 2

False Positive Results

• False positives are more common with preliminary screening tests compared to confirmatory tests 3
• Poppy seeds, pseudoephedrine, and dextromethorphan have been reported to cause false positive results 3
• Standard immunoassays lack specificity to distinguish between structurally similar compounds, resulting in false positive results, which is a significant clinical concern, as highlighted by the American Society of Addiction Medicine and the American Academy of Pediatrics 4, 2
• Urine drug screens can produce false positive results due to cross-reactivity between similar chemical structures, requiring confirmatory testing to avoid misdiagnosis and inappropriate patient management 4
• A positive opiate test may not detect all prescribed opioids, potentially leading to false accusations of non-adherence, and clinicians should consider the timing of last dose relative to testing, metabolic variations, and technical limitations of the assay, as recommended by the American Academy of Pain Medicine and the American Society of Addiction Medicine 2

Interpretation of Test Results

• The absence of a substance on a drug test does not definitively prove non-use; it may simply reflect test limitations or timing issues, and clinicians should consider the possibility of non-adherence to prescribed medication, timing issues related to last dose, or technical limitations of the test, according to the Clinical Infectious Diseases guidelines and the College of American Pathologists 5, 2
• When interpreting UDS results, healthcare providers should always obtain a complete medication history, including prescription and OTC medications, and consider the possibility of false positives with sympathomimetic medications, such as phentermine, as recommended by the American Academy of Pediatrics and the American Society of Addiction Medicine 4, 2
• Unexpected positive results should prompt a conversation with the patient rather than immediate punitive action, as recommended by the Infectious Diseases Society of America, with a strength of evidence supporting a patient-centered approach 2

Detection Windows for Various Substances

Management of Positive Test Results

• In cases of confirmed positive illicit methamphetamine screens, the American Academy of Child and Adolescent Psychiatry suggests intensifying monitoring and frequency of visits, considering referral to addiction treatment, and not immediately discontinuing ADHD treatment to avoid worsening outcomes 8
• For moderate-risk patients on chronic opioid therapy, presumptive urine drug testing 8 times per year is appropriate, and definitive testing should be reserved for situations where unexpected results occur, the patient disputes results, or there's clinical suspicion of use of substances not detected by standard immunoassay, as recommended by the CDC and the American Society of Addiction Medicine 1, 2

Xylazine and Its Effects

• Xylazine acts as an α-2 adrenergic receptor agonist in the brain, decreasing sympathetic nervous system outflow, causing sedation, relative hypotension, and bradycardia, as noted by the American College of Emergency Physicians and other authorities 6
• Naloxone will not reverse xylazine effects as it acts on α-2 receptors, not opioid receptors, and focus should be on supportive care with attention to ventilation and oxygenation, according to the American College of Emergency Physicians and the Clinical Infectious Diseases guidelines 6, 2
• Administering naloxone for the opioid component when xylazine is combined with opioids is recommended, as per the American College of Emergency Physicians and other authorities 6

Collaboration with Laboratory Toxicologists

• Establishing a working relationship with laboratory toxicologists who can assist with interpretation is crucial in optimizing detection of true positives, and using confirmatory testing when results will change treatment approach or patient education, as recommended by the College of American Pathologists and the American Society of Addiction Medicine 2, 5